This content is from: Premium

Transformers

Here are the top U.S. analysts who have adapted their research coverage to help hedge funds generate alpha.

ON MAY 10, 2007, the U.S. Food and Drug Administration held a nine-hour meeting over potential labeling changes for Aranesp, Amgen's best-selling drug, used to treat chemotherapy-induced anemia. Restrictions could annihilate sales at the Thousand Oaks, California­based biotechnology giant. Early the next morning hedge fund managers were scrambling to determine the impact the meeting would have

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content